RecruitingACTRN12609000233224
A Single-Dose Safety and Tolerability Placebo Controlled Study of Subcutaneous SCH 900222 in Healthy Volunteers
Sponsor
Schering-Plough
Enrollment
32 participants
Start Date
Jun 1, 2009
Study Type
Interventional
Conditions
Summary
This study will evaluate the safety, tolerability, & pharmacokinetic response to SCH 900222 subcutaneous fixed dose in healthy subjects.
Eligibility
Sex: Both males and femalesMin Age: 18 YearssMax Age: 45 Yearss
Inclusion Criteria1
- Male/Female Healthy volunteers must have no history of latent or active tuberculosis (TB) prior to screening
Exclusion Criteria1
- History of malignancy, Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C, active or latent mycobacterium tuberculosis
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A single dose of either 50mg or 200mg SCH 900222 administered as a subcutaneous single injection.
A single dose of either 50mg or 200mg SCH 900222 administered as a subcutaneous single injection.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000233224